Riik: Taiwan
keel: hiina
Allikas: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
BISOPROLOL HEMIFUMARATE
台灣默克股份有限公司 台北市內湖區堤頂大道2段89號6樓 (23526610)
C07AB07
膜衣錠
主成分 () ; BISOPROLOL HEMIFUMARATE (1216002820) (2:1)MG
鋁箔盒裝
製 劑
須由醫師處方使用
MERCK KGaA FRANKFURTER STRASSE 250, 64293 DARMSTADT/GERMANY、POSTFACH:64271 DARMSTADT/GERMANY DE
bisoprolol
穩定型慢性中度至重度心衰竭。
註銷日期: 2016/05/31; 註銷理由: 許可證已逾有效期; 有效日期: 2014/06/29; 英文品名: CONCOR 2.5
已註銷
2004-06-29
CONCOR ® 1.25 CONCOR ® 2.5 ACTIVE INGREDIENT: BISOPROLOL FUMARATE COMPOSITION Concor ® 1.25 Each film-coated tablet contains 1.25 mg bisoprolol fumarate as active ingredient. Excipients: Tablet core: Silica, colloidal anhydrous; magnesium stearate, crospovidone, microcrystalline cellulose, pregelatinized maize starch, maize starch, calcium hydrogen phosphate, anhydrous. Film coating: Dimethicone, talcum, macrogol 400, titanium dioxide, hypromellose. Concor ® 2.5 Each fil m-coated tablet contains 2.5 mg bisoprolol fumarate as active ingredient. Excipients: Tablet core: Silica, colloidal anhydrous; magnesium stearate, crospovidone, microcrystalline cellulose, maize starch, calcium hydrogen phosphate, anhydrous. Film coating: Dimethicone, macrogol 400, titanium dioxide, hypromellose. PROPERTIES PHARMACODYNAMICS Bisoprolol, the active ingredient of Concor ® , is a beta1-selective-adrenoceptor blocking agent, lacking intrinsic stimulating and relevant membrane stabilising activity. It only shows very low affinity to the beta2-receptor of the smooth muscles of bronchi and vessels as well as to the beta2-receptors concerned with metabolic regulation. Therefore, bisoprolol is generally not to be expected to influence the airway resistance and beta2-mediated metabolic effe cts. Its beta1-selectivity extends beyond the therapeutic dose range. PHARMACOKINETICS ABSORPTION. Bisoprolol is almost completely (> 90%) absorbed from the gastrointestinal tract and, because of its small first pass metabolism of approximately 10%, has an bioavailability of approximately 90% after oral administration. The bioavailability is not affected by food intake. Bisoprolol shows linear kineti cs and the plasma concentrations are proportional to the administered dose over the dose range 5 to 20 mg. Peak plasma concentrations occur within 2-3 hours. DISTRIBUTION. Bisoprolol is extensively distributed. The volume of distribution is 3.5 l/kg. Binding to plasma proteins is approximately 30%. METABOLISM. Bisoprolol is metabolised via oxidative pa Lugege kogu dokumenti